Crossmark

Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial

Crossref DOI link: https://doi.org/10.1186/s12986-020-00494-4

Published Online: 2020-08-26

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jafari-Maskouni, Saber

Shahraki, Mansour

Daneshi-Maskooni, Milad https://orcid.org/0000-0003-1373-1358
Dashipour, Alireza

Shamsi-Goushki, Ali

Mortazavi, Zinat
Funding

Funding for this research was provided by:

Zahedan University of Medical Sciences (IR.ZAUMS.REC.1397.332)
License Information

Text and Data Mining valid from 2020-08-26

Version of Record valid from 2020-08-26
More Information

Article History

Received: 21 January 2020

Accepted: 19 August 2020

First Online: 26 August 2020

Ethics approval and consent to participate

: This trial was approved by the Ethics Committee of Zahedan University of Medical Sciences (Ethical Code: IR.ZAUMS.REC.1397.332). A written informed consent form (in Persian) and informed assent (in Persian) obtained from all patients. Participation was free, and a patient could withdraw at whatever point the person feels he/she was unable to continue. The lifestyle advice was presented free to the patients and there was no bar to receiving the other health care services of the center. Side-effects of Bunium Persicum (Black Caraway) supplement (up to 2 g/day) have not been reported previously. The personal information of patients was kept secret before and after the study.

: There is no potential conflict of interest to research, authorship, and publication.

Document is current

Any future updates will be listed below